4bars
Full Member
- Joined
- Feb 10, 2016
- Messages
- 6,046
- Supports
- Barcelona
Speaking from extensive experience this is just incorrect. No one is making decisions on this basis. If that were the case there wouldn't be new oncology drugs.
Again there is plenty to criticize pharma companies for - all the bullshit patent games that they play, money wasted on marketing nonsense, all of the underhanded practices that limit competition, etc - but suggesting that they are focusing R&D on chronic treatments is simply incorrect.
It's also not really how R&D works - you can't just say "well they should focus more on curative treatments" as if investment will automatically lead to these types of breakthroughs. Curing diseases is incredibly hard - and you are downplaying the huge efforts that have moved the space in this direction (gene therapies, CAR-T, etc).
I think I already said that in my last comment:
"No, I don't say is EVIL BIG PHARMA and no, I am not saying that they don't cure or completely block drugs that might cure a disease". and I said this also " if a pharmaceutical company specialized in a chronicle solution and has an edge on a particular disease, they will not have incentive to cure it completely when they are already the experts."
Meaning that they will not push their R+D to undercut their own benefits
And also I said: " Sure. Nothing is black and white. The answer is in the middle..."